Patient and HCT characteristics of patients with TA-TMA vs no TA-TMA (n = 506)
| . | TA-TMA (n = 161) . | No TA-TMA (n = 345) . | P value . |
|---|---|---|---|
| Age (y), mean (range) . | 8.3 (0.3-25.9) . | 8.0 (0.1-28.6) . | .776∗ . |
| . | n (%) . | n (%) . | . |
| Sex | |||
| Male | 103 (64) | 201 (58) | .222† |
| Female | 58 (36) | 144 (42) | |
| Race | .525† | ||
| Caucasian | 107 (80) | 255 (81) | |
| Black | 2 (1) | 11 (4) | |
| Asian | 5 (4) | 8 (3) | |
| Other | 20 (15) | 39 (12) | |
| Unknown | 27 | 32 | |
| Ethnicity | .239† | ||
| Hispanic | 14 (19) | 27 (13) | |
| Non-Hispanic | 59 (81) | 174 (87) | |
| Unknown | 88 | 144 | |
| Transplant indication | ND | ||
| Benign hematologic condition | 27 (17) | 76 (22) | |
| Hematologic malignancy | 49 (30) | 92 (27) | |
| Immune deficiency | 40 (25) | 48 (14) | |
| Solid tumor | 21 (13) | 86 (25) | |
| Other | 24 (15) | 43 (12) | |
| HCT type | <.001‡ | ||
| Allogeneic | 137 (85) | 238 (69) | |
| Autologous | 24 (15) | 107 (31) | |
| Donor | .057§ | ||
| Related | 39 (24) | 91 (26) | |
| Unrelated | 98 (61) | 147 (43) | |
| Not applicable (ie, autologous transplant) | 24 (15) | 107 (31) | |
| Cell source | <.001|| | ||
| BM | 100 (62) | 187 (55) | |
| Cord | 19 (12) | 15 (4) | |
| PBSC | 40 (25) | 136 (41) | |
| Unknown | 2 | 7 | |
| HLA mismatch | .072¶ | ||
| Mismatch | 56 (40) | 85 (31) | |
| No mismatch | 85 (60) | 190 (69) | |
| NA (autologous) | 20 | 70 | |
| Conditioning intensity | ND | ||
| Myeloablative | 88 (57) | 211 (70) | |
| Reduced intensity | 58 (37) | 84 (28) | |
| Nonmyeloablative | 9 (6) | 7 (2) | |
| None | 0 (0) | 1 (0.003) | |
| Unknown | 6 | 42 | |
| HCT number | .002† | ||
| 1 | 94 (84) | 172 (94) | |
| 2 | 18 (16) | 9 (5) | |
| 3 | 0 (0) | 2 (1) | |
| Unknown | 49 | 162 | |
| Engraftment failure | 8 (5) | 0 (0) | <.001† |
| VOD | 11 (7) | 8 (2) | .007† |
| Maximum acute GVHD | <.001† | ||
| Grade 0 | 120 (75) | 305 (89) | |
| Grade 1-2 | 14 (9) | 28 (8) | |
| Grade 3-4 | 27 (17) | 12 (3) | |
| Infections in the first 100 d | <.001#,† | ||
| Yes | 89 (55) | 80 (23) | |
| No | 72 (45) | 265 (77) |
| . | TA-TMA (n = 161) . | No TA-TMA (n = 345) . | P value . |
|---|---|---|---|
| Age (y), mean (range) . | 8.3 (0.3-25.9) . | 8.0 (0.1-28.6) . | .776∗ . |
| . | n (%) . | n (%) . | . |
| Sex | |||
| Male | 103 (64) | 201 (58) | .222† |
| Female | 58 (36) | 144 (42) | |
| Race | .525† | ||
| Caucasian | 107 (80) | 255 (81) | |
| Black | 2 (1) | 11 (4) | |
| Asian | 5 (4) | 8 (3) | |
| Other | 20 (15) | 39 (12) | |
| Unknown | 27 | 32 | |
| Ethnicity | .239† | ||
| Hispanic | 14 (19) | 27 (13) | |
| Non-Hispanic | 59 (81) | 174 (87) | |
| Unknown | 88 | 144 | |
| Transplant indication | ND | ||
| Benign hematologic condition | 27 (17) | 76 (22) | |
| Hematologic malignancy | 49 (30) | 92 (27) | |
| Immune deficiency | 40 (25) | 48 (14) | |
| Solid tumor | 21 (13) | 86 (25) | |
| Other | 24 (15) | 43 (12) | |
| HCT type | <.001‡ | ||
| Allogeneic | 137 (85) | 238 (69) | |
| Autologous | 24 (15) | 107 (31) | |
| Donor | .057§ | ||
| Related | 39 (24) | 91 (26) | |
| Unrelated | 98 (61) | 147 (43) | |
| Not applicable (ie, autologous transplant) | 24 (15) | 107 (31) | |
| Cell source | <.001|| | ||
| BM | 100 (62) | 187 (55) | |
| Cord | 19 (12) | 15 (4) | |
| PBSC | 40 (25) | 136 (41) | |
| Unknown | 2 | 7 | |
| HLA mismatch | .072¶ | ||
| Mismatch | 56 (40) | 85 (31) | |
| No mismatch | 85 (60) | 190 (69) | |
| NA (autologous) | 20 | 70 | |
| Conditioning intensity | ND | ||
| Myeloablative | 88 (57) | 211 (70) | |
| Reduced intensity | 58 (37) | 84 (28) | |
| Nonmyeloablative | 9 (6) | 7 (2) | |
| None | 0 (0) | 1 (0.003) | |
| Unknown | 6 | 42 | |
| HCT number | .002† | ||
| 1 | 94 (84) | 172 (94) | |
| 2 | 18 (16) | 9 (5) | |
| 3 | 0 (0) | 2 (1) | |
| Unknown | 49 | 162 | |
| Engraftment failure | 8 (5) | 0 (0) | <.001† |
| VOD | 11 (7) | 8 (2) | .007† |
| Maximum acute GVHD | <.001† | ||
| Grade 0 | 120 (75) | 305 (89) | |
| Grade 1-2 | 14 (9) | 28 (8) | |
| Grade 3-4 | 27 (17) | 12 (3) | |
| Infections in the first 100 d | <.001#,† | ||
| Yes | 89 (55) | 80 (23) | |
| No | 72 (45) | 265 (77) |
| Day 15 to day 365 after HCT . | Median (range) . | Median (range) . | . |
|---|---|---|---|
| Inpatient cost per day ($) | 4 369 (2 201-31 108) | 4 228 (2 275-27 012) | .490∗∗ |
| Total cost ($) | 470 493 (71 099-7 217 095) | 285 009 (21 531-6 212 835) | <.001∗∗ |
| Number of inpatient days | 87 (22-411) | 58 (6-489) | <.001∗∗ |
| Number of post-HCT days from TA-TMA | 26 (0-97) | ND | ND |
| ICU | <.001† | ||
| Admitted, n (%) | 58 (36) | 35 (10) | |
| Not admitted, n (%) | 103 (64) | 310 (90) | |
| ICU admission days | 18 (0-162) | 12 (0-90) | .135∗∗ |
| Day 15 to day 365 after HCT . | Median (range) . | Median (range) . | . |
|---|---|---|---|
| Inpatient cost per day ($) | 4 369 (2 201-31 108) | 4 228 (2 275-27 012) | .490∗∗ |
| Total cost ($) | 470 493 (71 099-7 217 095) | 285 009 (21 531-6 212 835) | <.001∗∗ |
| Number of inpatient days | 87 (22-411) | 58 (6-489) | <.001∗∗ |
| Number of post-HCT days from TA-TMA | 26 (0-97) | ND | ND |
| ICU | <.001† | ||
| Admitted, n (%) | 58 (36) | 35 (10) | |
| Not admitted, n (%) | 103 (64) | 310 (90) | |
| ICU admission days | 18 (0-162) | 12 (0-90) | .135∗∗ |
| . | OS ± SE (%) . | OS ± SE (%) . | P value . |
|---|---|---|---|
| OS | <.001†† | ||
| 100-d | 90.6 ± 2.3 | 98.2 ± 0.7 | |
| 180-d | 83.6 ± 2.9 | 97.3 ± 0.8 | |
| 1-y | 74.9 ± 3.5 | 92.6 ± 1.5 |
| . | OS ± SE (%) . | OS ± SE (%) . | P value . |
|---|---|---|---|
| OS | <.001†† | ||
| 100-d | 90.6 ± 2.3 | 98.2 ± 0.7 | |
| 180-d | 83.6 ± 2.9 | 97.3 ± 0.8 | |
| 1-y | 74.9 ± 3.5 | 92.6 ± 1.5 |
BM, bone marrow; BMF, bone marrow failure; ND, not done; PBSC, peripheral blood stem cells; VOD, veno-occlusive disease.
t test.
Fisher exact test.
Fisher exact test: comparison of allogeneic vs autologous.
Fisher exact test: comparison of related vs unrelated.
χ2 test: comparison of BM, cord, and PBSC as cell sources.
Fisher exact test: comparison of mismatch vs no mismatch.
Some patients had more than 1 infection.
Mann-Whitney test.
Log-rank test.